Medicine Recommendations

Central precocious puberty (onset before 8 years in girls and 10 years in boys)

a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.

Hospital specialist initiation only for long term severe and disabling depressive illness, after trial of standard antidepressant treatment and as an adjunct to other antidepressant medication

Except for mitochondrial disorders

Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed.

MHRA Aug 2018 Update - Ulipristal

Drug Safety Update March 2020 - Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

COPD

COPD

NICE TA665 - Upadacitinib for treating severe rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

For treating moderately to severely active ulcerative colitis - Nice TA856

NICE TA 865 - Upadacitinib for treating moderately to severely active ulcerative colitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Treating moderate to severe atopic dermatitis - NICE TA814

NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)

NICE TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Treating active ankylosing spondylitis - NICE TA829

NICE TA829 - Upadacitinib for treating active ankylosing spondylitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

NICE TA744 - Upadacitinib for treating moderate rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Upadacitinib for previously treated moderately to severely active Crohn’s disease

NICE TA 905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease

Ustekinumab for treating moderately to severely active ulcerative colitis (TA 633)

Treatment of active psoriatic arthritis - rapid review of TA 313 (NICE TA340)

NICE TA 340 - Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) 

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderate to severe plaque psoriasis (NICE TA180)

NICE TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderately to severely active Crohn’s disease after previous treatment (NICE TA456)

NICE TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment

For the management of foot ulcers in the diabetic population